Suppr超能文献

日本活体供肝肝移植治疗肝细胞癌标准的全国性队列研究。

Japanese living donor liver transplantation criteria for hepatocellular carcinoma: nationwide cohort study.

机构信息

Department of Gastroenterological and Transplant Surgery, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.

Medical Centre for Translational and Clinical Research, Hiroshima University Hospital, Hiroshima, Japan.

出版信息

BJS Open. 2024 Jul 2;8(4). doi: 10.1093/bjsopen/zrae079.

Abstract

BACKGROUND

Validating the expanded criteria for living donor liver transplantation for hepatocellular carcinoma using national data is highly significant. The aim of this study was to evaluate the validity of the new Japanese criteria for living donor liver transplantation for hepatocellular carcinoma patients and identify factors associated with a poor prognosis using the Japanese national data set.

METHODS

The study population comprised patients who underwent living donor liver transplantation for hepatocellular carcinoma at 37 centres in Japan between 2010 and 2018. In a nationwide survey, the overall survival and recurrence-free survival rates were evaluated based on the new Japanese criteria for applying the 5-5-500 rule when extending the indication beyond the Milan criteria. Prognostic factors within the Japanese criteria were determined using the Cox proportional hazards model.

RESULTS

Patients within (485 patients) and beyond (31 patients) the Japanese criteria exhibited 5-year overall survival rates of 81% and 58% and 5-year recurrence-free survival rates of 77% and 48% respectively. Patients who met the Milan criteria, but not the 5-5-500 rule, had poorer outcomes. Multivariate analysis for 474 patients identified a neutrophil-to-lymphocyte ratio greater than or equal to 5 and a history of hepatectomy as independent risk factors.

CONCLUSION

This nationwide survey confirms the validity of the Japanese criteria. The poor prognostic factors within the Japanese criteria include a neutrophil-to-lymphocyte ratio greater than or equal to 5 and previous hepatectomy.

摘要

背景

使用国家数据验证扩大的肝癌活体供肝移植标准具有重要意义。本研究旨在使用日本国家数据集评估新的日本肝癌活体供肝移植标准的有效性,并确定与不良预后相关的因素。

方法

研究人群包括 2010 年至 2018 年在日本 37 个中心接受活体供肝移植治疗肝癌的患者。在一项全国性调查中,根据将米兰标准的适应证扩大至 5-5-500 规则时应用新的日本标准,评估总体生存率和无复发生存率。使用 Cox 比例风险模型确定日本标准内的预后因素。

结果

符合日本标准内(485 例)和标准外(31 例)的患者 5 年总生存率分别为 81%和 58%,5 年无复发生存率分别为 77%和 48%。符合米兰标准但不符合 5-5-500 规则的患者预后较差。对 474 例患者的多变量分析确定,中性粒细胞与淋巴细胞比值大于或等于 5 和肝切除术史为独立的危险因素。

结论

本全国性调查证实了日本标准的有效性。日本标准内的不良预后因素包括中性粒细胞与淋巴细胞比值大于或等于 5 和既往肝切除术。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6145/11295212/bd6e4353ecf3/zrae079f1.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验